Working… Menu

Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03850886
Recruitment Status : Recruiting
First Posted : February 22, 2019
Last Update Posted : February 22, 2019
Information provided by (Responsible Party):
Rasha Roshdy Ibrahim El-kady, Ain Shams University

Brief Summary:
The purpose of the study is to evaluate the efficacy and safety of Niacinamide supplementation on clinical outcome of fatty liver patients having type II DM through measurement of the following before and after Niacinamide administration: Liver enzymes, Lipid profie, HOMA-IR, Oxidative stress markers and endothelial dysfunction marker. Fibroscan with CAP will be done at baseline and at the end of the trial. Also, Evaluation of quality of life of patients before and after Niacinamide administration using Chronic Liver Disease questionnaire.

Condition or disease Intervention/treatment Phase
Non Alcoholic Fatty Liver Disease Dietary Supplement: Niacinamide Oral Tablet Drug: Antidiabetic Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Efficacy and Safety of Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients
Actual Study Start Date : January 15, 2019
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : April 2019

Arm Intervention/treatment
Experimental: Niacinamide group
Niacinamide oral tablets as Nature's Life 1000 mg tablets once daily for 3 months diabetes management including metformin or Sulphonylurea
Dietary Supplement: Niacinamide Oral Tablet
Nature's Life Niacinamide 1000 mg
Other Names:
  • Nicotinamide
  • Vitamin B3

Drug: Antidiabetic
Metformin or Sulphonylurea

Active Comparator: Control group
diabetes management including metformin or Sulphonylurea
Drug: Antidiabetic
Metformin or Sulphonylurea

Primary Outcome Measures :
  1. Steatosis using Fibroscan with CAP [ Time Frame: 3 months ]
    using Fibroscan with CAP

  2. Adiponectin mesurement [ Time Frame: 3 months ]
    Endothelial dysfunction

Secondary Outcome Measures :
  1. Malondialdehyde [ Time Frame: 3 monthes ]
    Oxidative stress marker

  2. HOMA-IR [ Time Frame: 3 months ]
    Insulin resistance

  3. ALT, AST [ Time Frame: 3 months ]
    Liver enzymes

  4. LDL, cholesterol [ Time Frame: 3 months ]
    Lipid markers

Other Outcome Measures:
  1. Chronic Liver Disease Questionnaire [ Time Frame: 3 months ]
    quality of measurement

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 1. Male or female outpatients age 18 to 70 years old. 2. The diagnosis of NAFLD will be established according to the appearance of fatty liver on US or elevated liver enzymes (>1.5 times normal level).

Exclusion Criteria:

  • 1. History of alcohol abuse (as defined by an average daily consumption of alcohol > 30 g/day in men and > 20 g/day in women).

    2. Cirrhotic patients.

  • Fibroscan result > 12Kpa or as
  • predicted from FIB 4 score > 3.25

FIB-4 = age (yr) * AST (IU/L)/platelet count (109/L) * ALT1/2 (IU/L) 3. Hyper / hypoparathyroidism. 4. Cancer. 5. Viral hepatitis. 6. Biliary disease. 7. Autoimmune hepatitis 8. Other causes of liver disease (hemochromatosis, Wilson's disease). 9. Participants who took antibiotics, probiotic supplements and/or hepatotoxic medicines (NSAIDs, Amiodarone and methotrexate) within 6 months before the start of the study and during the study.

10. Ascetic patients and congestive heart failure patients will be excluded due to unreliability of Fibroscan results in them.

11. Pregnancy and lactation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03850886

Layout table for location contacts
Contact: Rasha El-kady, MD 01000252142

Layout table for location information
AlZahraa hospital Recruiting
Cairo, Egypt, 02
Contact: Rasha El-kady         
Sponsors and Collaborators
Ain Shams University

Layout table for additonal information
Responsible Party: Rasha Roshdy Ibrahim El-kady, Teaching assisstant at department clinical pharmacy, Ain Shams University Identifier: NCT03850886     History of Changes
Other Study ID Numbers: PHCL79
First Posted: February 22, 2019    Key Record Dates
Last Update Posted: February 22, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases
Nicotinic Acids
Hypoglycemic Agents
Physiological Effects of Drugs
Vitamin B Complex
Growth Substances
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Vasodilator Agents